Compare Peptides

Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.

Popular comparisons

CJC-1295

CJC-1295 with DAC, CJC-1295 no DAC

Category 1
Growth Hormone Secretagogue

Ipamorelin

Category 1
Growth Hormone Secretagogue
Overview

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone. Available with or without a Drug Affinity Complex (DAC) that extends its half-life.

A selective growth hormone secretagogue that stimulates GH release with minimal effects on cortisol and prolactin. Considered one of the 'cleanest' GH-releasing peptides due to its selectivity.

Mechanism of Action

Binds to GHRH receptors on the pituitary gland, stimulating pulsatile release of growth hormone. The DAC version binds to albumin in the blood, extending the half-life from minutes to approximately 6-8 days.

Binds to ghrelin receptors (GHS-R) in the pituitary gland, triggering pulsatile growth hormone release. Unlike other GH secretagogues, it does not significantly increase cortisol, ACTH, or prolactin levels.

Common Uses
  • Growth hormone optimization
  • Improved sleep quality
  • Fat loss
  • Muscle recovery
  • Anti-aging protocols
  • Growth hormone optimization
  • Improved sleep quality
  • Fat loss
  • Muscle recovery and growth
  • Anti-aging protocols
Known Risks
  • Water retention
  • Tingling or numbness
  • Potential cortisol elevation
  • Limited long-term safety data
  • May affect blood sugar levels
  • Headaches
  • Water retention
  • Tingling sensations
  • Limited long-term human data
  • May affect blood sugar
Regulatory Status
Category 1

Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.

Category 1

Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.

This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.